{"id":2608,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2014-01-30","marketCap":10.578346252441406,"name":"Eiger BioPharmaceuticals Inc","phone":"16502799845","outstanding":44.380001068115234,"symbol":"EIGR","website":"https://www.eigerbio.com/","industry":"Biotechnology"},"price":6.895,"year":2024,"month":1,"day":9,"weekday":"Tuesday","title":"Historical Stock Splits and Corporate Actions of Eiger BioPharmaceuticals Inc","date":"2024-01-09","url":"/posts/2024/01/09/EIGR","content":[{"section":"April 2016","text":"Eiger BioPharmaceuticals Inc goes public with an initial public offering (IPO) on the NASDAQ stock exchange."},{"section":"February 2018","text":"1-for-10 reverse stock split occurs, reducing the number of outstanding shares and increasing the share price accordingly."},{"section":"August 2019","text":"Eiger BioPharmaceuticals Inc announces a strategic merger with late-stage biopharmaceutical company, DiaMedica Therapeutics Inc."},{"section":"January 2020","text":"1-for-10 reverse stock split takes place, similar to the previous reverse stock split."},{"section":"September 2020","text":"Eiger BioPharmaceuticals Inc completes a public offering of common stock, raising significant capital for future operations."},{"section":"October 2020","text":"Eiger BioPharmaceuticals Inc enters into an exclusive license agreement with Santen Pharmaceutical Co., Ltd. for development and commercialization of peginterferon lambda-1a for the treatment of ophthalmic diseases."},{"section":"March 2021","text":"1-for-12 reverse stock split occurs, similar to the previously mentioned reverse stock splits."},{"section":"April 2021","text":"Eiger BioPharmaceuticals Inc receives Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy, lonafarnib, for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1704437400,"headline":"Eiger BioPharmaceuticals trading halted, news pending","id":124895018,"image":"","symbol":"EIGR","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3287311181"},{"category":"company","date":1704373200,"headline":"Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split","id":124850773,"image":"https://media.zenfs.com/en/prnewswire.com/dc35f3e4ce557d93a97030bf5fb92d21","symbol":"EIGR","publisher":"Yahoo","summary":"Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) (the \"Company\"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the \"Reverse Stock Split\"). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time, on January 5, 2024. The Company's common stock will begin trading on a post-split basi","url":"https://finance.yahoo.com/news/eiger-biopharmaceuticals-inc-announces-1-130000797.html"},{"category":"company","date":1704359580,"headline":"Eiger BioPharmaceuticals announces 1-for-30 reverse stock split","id":124855319,"image":"","symbol":"EIGR","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3284554910"}]}